Primary Care Clinics in New Paris, PA Accepting Medicare
5 Primary Care Clinics found. Showing 1 - 5
 Orchard Valley Physician Services Pllc Family Medicine Medicare: Medicare Enrolled Practice Location: 4186 Cortland Dr, New Paris, PA 15554 Phone: 814-839-4108 Fax: 814-839-4845 |
Conemaugh Physician Group - New Paris Clinic/Center - Rural Health Medicare: Not Enrolled in Medicare Practice Location: 4186 Cortland Dr, New Paris, PA 15554 Phone: 814-839-4108 Fax: 814-839-4845 |
Conemaugh Health Initiatives Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4186 Cortland Drive, Box 367, New Paris, PA 15554 Phone: 814-839-4108 Fax: 814-839-4845 |
Henry W. Shoenthal, Md Inc Family Medicine Medicare: Medicare Enrolled Practice Location: 4186 Cortland Dr, New Paris, PA 15554 Phone: 814-839-4108 Fax: 814-839-4845 |
New Paris Rural Health Clinic Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 4186 Cortland Avenue, New Paris, PA 15554 Phone: 814-839-4108 Fax: 814-839-4845 |
News Archive
Obese patients with COPD improve following pulmonary rehabilitation program: Research
Obese patients with chronic obstructive pulmonary disease stand to gain as much from pulmonary rehabilitation as their slimmer counterparts, even though as a group they have a lower exercise capacity, according to new research from the University Hospitals of Leicester in the UK.
FDA approves Lannett's ANDA for Phentermine Resin Extended-Release Capsules
Lannett Company, Inc. today announced the U.S. Food and Drug Administration (FDA) approved its Abbreviated New Drug Application (ANDA) for Phentermine Resin Extended-Release Capsules, 15 mg and 30 mg, representing the fourth product approval the company has received in the last five weeks.
ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009
ImmunoCellular Therapeutics announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.
Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting
Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.
› Verified 1 days ago